HK1095135A1 - Morpholine derivatives as norepinephrine reuptake inhibitors - Google Patents

Morpholine derivatives as norepinephrine reuptake inhibitors

Info

Publication number
HK1095135A1
HK1095135A1 HK07100215.2A HK07100215A HK1095135A1 HK 1095135 A1 HK1095135 A1 HK 1095135A1 HK 07100215 A HK07100215 A HK 07100215A HK 1095135 A1 HK1095135 A1 HK 1095135A1
Authority
HK
Hong Kong
Prior art keywords
reuptake inhibitors
norepinephrine reuptake
morpholine derivatives
morpholine
derivatives
Prior art date
Application number
HK07100215.2A
Other languages
English (en)
Inventor
Gordon Iain Campbell
Manuel J Cases-Thomas
Teresa Man
John Joseph Masters
Helene Rudyk
Magnus Wilhelm Walter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1095135(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1095135A1 publication Critical patent/HK1095135A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
HK07100215.2A 2003-11-10 2007-01-05 Morpholine derivatives as norepinephrine reuptake inhibitors HK1095135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0326148.4A GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives
US53545904P 2004-01-09 2004-01-09
PCT/US2004/032771 WO2005047272A1 (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors

Publications (1)

Publication Number Publication Date
HK1095135A1 true HK1095135A1 (en) 2007-04-27

Family

ID=29726235

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100215.2A HK1095135A1 (en) 2003-11-10 2007-01-05 Morpholine derivatives as norepinephrine reuptake inhibitors

Country Status (34)

Country Link
US (1) US7423037B2 (xx)
EP (2) EP1682523B1 (xx)
JP (1) JP4850068B2 (xx)
KR (1) KR100783855B1 (xx)
CN (1) CN1878762B (xx)
AR (1) AR046927A1 (xx)
AT (1) ATE478057T1 (xx)
AU (1) AU2004289616B2 (xx)
BR (1) BRPI0415273B8 (xx)
CA (1) CA2544649C (xx)
CR (1) CR8390A (xx)
CY (1) CY1110796T1 (xx)
DE (1) DE602004028750D1 (xx)
DK (1) DK1682523T3 (xx)
EA (1) EA009960B1 (xx)
EC (1) ECSP066555A (xx)
ES (1) ES2348872T3 (xx)
GB (1) GB0326148D0 (xx)
HK (1) HK1095135A1 (xx)
HR (1) HRP20100476T1 (xx)
IL (1) IL175365A (xx)
MA (1) MA28330A1 (xx)
MY (1) MY141048A (xx)
NO (1) NO336268B1 (xx)
NZ (1) NZ546067A (xx)
PE (1) PE20050491A1 (xx)
PL (1) PL1682523T3 (xx)
PT (1) PT1682523E (xx)
SI (1) SI1682523T1 (xx)
SV (1) SV2006001934A (xx)
TW (1) TWI339658B (xx)
UA (1) UA85198C2 (xx)
WO (1) WO2005047272A1 (xx)
ZA (1) ZA200603680B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399557T1 (de) * 2003-12-12 2008-07-15 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
RU2613633C1 (ru) * 2016-03-09 2017-03-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
NL108827C (xx) 1956-04-09
GB895309A (en) 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3141823A (en) 1962-09-04 1964-07-21 Res Lab Dr C Janssen N V Method for producing analgesia
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1999015177A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
NZ520349A (en) * 1998-01-21 2004-02-27 Glaxo Group Ltd (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2- morpholinol and its salts and pharmaceuticals thereof
AU5889100A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DK1632234T3 (da) * 1999-07-01 2007-09-17 Pharmacia & Upjohn Co Llc (S,S)-reboxetin til behandling af kronisk træthedssyndrom
GB0120461D0 (en) * 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd 1−(1−置換カルボニル−4−ピペリジニルメチル)ピペリジン誘導体およびそれを含有する医薬組成物
FR2852954B1 (fr) * 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PE20050491A1 (es) 2005-08-24
CY1110796T1 (el) 2015-06-10
CR8390A (es) 2007-12-07
CN1878762B (zh) 2010-10-27
SV2006001934A (es) 2006-02-15
WO2005047272A1 (en) 2005-05-26
MY141048A (en) 2010-02-25
TW200524885A (en) 2005-08-01
EP1682523A1 (en) 2006-07-26
CN1878762A (zh) 2006-12-13
PT1682523E (pt) 2010-09-20
PL1682523T3 (pl) 2011-01-31
ZA200603680B (en) 2007-07-25
NO20062700L (no) 2006-08-08
US20070083046A1 (en) 2007-04-12
HRP20100476T1 (hr) 2010-10-31
DK1682523T3 (da) 2010-11-15
JP4850068B2 (ja) 2012-01-11
AR046927A1 (es) 2006-01-04
KR20060086408A (ko) 2006-07-31
JP2007510720A (ja) 2007-04-26
IL175365A (en) 2011-02-28
KR100783855B1 (ko) 2007-12-10
BRPI0415273B8 (pt) 2021-05-25
DE602004028750D1 (de) 2010-09-30
ECSP066555A (es) 2006-10-17
GB0326148D0 (en) 2003-12-17
US7423037B2 (en) 2008-09-09
TWI339658B (en) 2011-04-01
AU2004289616A1 (en) 2005-05-26
NZ546067A (en) 2009-04-30
AU2004289616B2 (en) 2010-08-05
EP2223916A1 (en) 2010-09-01
MA28330A1 (fr) 2006-12-01
IL175365A0 (en) 2006-09-05
BRPI0415273B1 (pt) 2019-04-30
BRPI0415273A (pt) 2006-12-19
EA200600945A1 (ru) 2006-10-27
EP1682523B1 (en) 2010-08-18
EA009960B1 (ru) 2008-04-28
CA2544649A1 (en) 2005-05-26
CA2544649C (en) 2012-08-14
SI1682523T1 (sl) 2010-12-31
ES2348872T3 (es) 2010-12-16
ATE478057T1 (de) 2010-09-15
NO336268B1 (no) 2015-07-06
UA85198C2 (ru) 2009-01-12

Similar Documents

Publication Publication Date Title
HUS1400012I1 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL178313A0 (en) Morpholine compounds
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
HK1087331A1 (en) Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
PL364580A1 (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
HK1101871A1 (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
EP1801108A4 (en) morpholine
AP2005003467A0 (en) N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
HK1096968A1 (en) Aminopyridine-derivatives as inductible no-synthase inhibitors
HK1095135A1 (en) Morpholine derivatives as norepinephrine reuptake inhibitors
GB0308460D0 (en) Morpholine dopamine agonists
GB0313606D0 (en) Morpholine dopamine agonists